 SOUTH PLAINFIELD, N.J., Sept. 20, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT today presented real-world results from the STRIDE patient registry demonstrating that treatment with TranslarnaTM ataluren delays loss of ambulation by more than five years in boys with nonsense mutation Duchenne muscular dystrophy nmDMD compared to standard of care SoC alone. 